Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 2
2008 1
2009 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

7 results

Results by year

Filters applied: . Clear all
Page 1
Diabetic retinopathy and angiogenesis.
Crawford TN, Alfaro DV 3rd, Kerrison JB, Jablon EP. Crawford TN, et al. Among authors: jablon ep. Curr Diabetes Rev. 2009 Feb;5(1):8-13. doi: 10.2174/157339909787314149. Curr Diabetes Rev. 2009. PMID: 19199892 Review.
Ranibizumab for diabetic retinopathy.
Rodriguez-Fontal M, Alfaro V, Kerrison JB, Jablon EP. Rodriguez-Fontal M, et al. Among authors: jablon ep. Curr Diabetes Rev. 2009 Feb;5(1):47-51. doi: 10.2174/157339909787314239. Curr Diabetes Rev. 2009. PMID: 19199898 Review.
Fishing-related ocular trauma.
Alfaro DV 3rd, Jablon EP, Rodriguez Fontal M, Villalba SJ, Morris RE, Grossman M, Roig-Melo E. Alfaro DV 3rd, et al. Among authors: jablon ep. Am J Ophthalmol. 2005 Mar;139(3):488-92. doi: 10.1016/j.ajo.2004.10.011. Am J Ophthalmol. 2005. PMID: 15767058
Metabolic control and diabetic retinopathy.
Rodriguez-Fontal M, Kerrison JB, Alfaro DV, Jablon EP. Rodriguez-Fontal M, et al. Among authors: jablon ep. Curr Diabetes Rev. 2009 Feb;5(1):3-7. doi: 10.2174/157339909787314176. Curr Diabetes Rev. 2009. PMID: 19199891 Review.
Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2/3 trial.
Brown DM, Boyer DS, Do DV, Wykoff CC, Sakamoto T, Win P, Joshi S, Salehi-Had H, Seres A, Berliner AJ, Leal S, Vitti R, Chu KW, Reed K, Rao R, Cheng Y, Sun W, Voronca D, Bhore R, Schmidt-Ott U, Schmelter T, Schulze A, Zhang X, Hirshberg B, Yancopoulos GD, Sivaprasad S; PHOTON Investigators. Brown DM, et al. Lancet. 2024 Mar 23;403(10432):1153-1163. doi: 10.1016/S0140-6736(23)02577-1. Epub 2024 Mar 7. Lancet. 2024. PMID: 38461843 Clinical Trial.